Comparative Pharmacology
Head-to-head clinical analysis: ISRADIPINE versus PROCARDIA XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISRADIPINE versus PROCARDIA XL.
ISRADIPINE vs PROCARDIA XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance.
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
30-90 mg orally once daily, extended-release tablet.
None Documented
None Documented
Clinical Note
moderateIsradipine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid."
Clinical Note
moderateIsradipine + Furosemide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide."
Clinical Note
moderateIsradipine + Bumetanide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide."
Clinical Note
moderateIsradipine + Travoprost
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
Terminal elimination half-life: 6-11 hours; clinical context: steady-state achieved after 2-3 days of once-daily dosing.
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Renal: 70-80% as metabolites, <1% unchanged; Fecal: 15-20% via bile.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker
"Isradipine may increase the hypotensive activities of Travoprost."